What's Left to Prescribe a Man Allergic to One Class and About to Ride a Motorcycle Through Three More
Take away the first-line agent for a real allergy, and the second-line agent for an FDA warning that happens to land exactly on his own physical plans, and what's actually left turns out to matter more than which drug wins on paper.
Gerald T., a 63-year-old man, retired from thirty-one years managing a regional distribution warehouse this past spring, and has spent most of the months since planning a solo cross-country motorcycle trip he's wanted to take since his twenties — routing, gear, a list of diners along old Route 2 he's already bookmarked. A 7mm stone in his mid-ureter, found incidentally and asymptomatic so far, is scheduled for ureteroscopy three weeks before his departure date, which he's mentioned twice is not moving regardless of what the stone does. He carries a documented history of anaphylaxis to penicillin as a teenager, confirmed by a formal allergy workup in his thirties after a near-miss with a prescribed cephalosporin — a genuine, disqualifying history, not a vague rash he can't quite remember.
Perioperative antimicrobial prophylaxis before ureteroscopy is usually a simple single-dose cephalosporin, which is exactly the drug his allergy history rules out. The traditional second-line choice, a fluoroquinolone, has accumulated FDA warnings for eighteen years: a boxed warning for tendinitis and tendon rupture in July 2008, possibly permanent peripheral neuropathy in August 2013, a revised boxed warning in July 2016 for disabling and potentially permanent effects across tendons, muscles, joints, nerves and the central nervous system, and aortic aneurysm and dissection in December 2018. The agency's instruction to reserve the class for patients with no other option is narrower than it is usually quoted — it names sinusitis, bronchitis and uncomplicated UTI, not surgical prophylaxis, so it does not literally govern Gerald's case. What does govern it is the tendon and neuropathy signal itself, landing on a man about to spend weeks alone on a motorcycle depending on tendons and balance holding up exactly the way they are supposed to. That leaves two agents still standing, both supported by his own antibiogram, and a man who has now told this clinic twice that his departure date is not moving.
Pre-op planning, three weeks out
His documented anaphylaxis to penicillin, with a confirmed near-miss on a cephalosporin, takes our usual first-line agent off the table outright. Our local antibiogram shows low resistance to aminoglycosides among the organisms we'd expect — I'd give single-dose gentamicin.
Single-dose exposure has a well-established safety profile, distinct from the nephrotoxicity/ototoxicity concerns that come with prolonged dosing.
Gentamicin is reasonable, and I won't argue the single-dose safety data is wrong. But I'd reach for fosfomycin first — a single oral dose, narrower spectrum, no injection or monitoring, and it avoids an aminoglycoside in someone we don't strictly need one in.
I'll say plainly that most of fosfomycin's trial evidence comes from transrectal prostate biopsy prophylaxis rather than ureteroscopy specifically — that's a real gap, not something to gloss over. But the mechanism and spectrum both transfer reasonably well.
Both of those are reasonable choices in the abstract, and I don't think either of you is wrong on the pharmacology. What tips it for me is something neither of you has weighted yet: Gerald is riding solo, cross-country, on a motorcycle, three weeks after this procedure.
Aminoglycoside vestibular toxicity is rare at single-dose exposure, but it's exactly the kind of rare event that would be catastrophically worse-timed for a man depending on his own balance alone on a bike than it would be for almost anyone else. That's not incidental color — it's a real, patient-specific reason to prefer fosfomycin here even though the choice between them is otherwise close.
Given the antibiogram supports either agent working, I'd let Gerald's own plans be the deciding factor rather than treat this as a coin flip.
Agreed: single 3g oral dose of fosfomycin, given the day of the procedure. The Urologist's preference for gentamicin wasn't wrong on the pharmacology — it was outweighed once Gerald's own stated plans were treated as a real input to the decision rather than incidental detail.
Gerald was told explicitly why fluoroquinolones were avoided, including the specific tendon and neuropathy warnings, and told that the FDA's formal reserve-use restriction names other indications rather than this one, so he understands the reasoning if he encounters ciprofloxacin prescribed elsewhere for an unrelated issue during his trip.